Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder.

Lancet

Department of Haematology, Saint Bartholomew's and The Royal London Hospital, Queen Mary's School of Medicine, University of London, Medical College Building, Turner Street, E1 2AD, London, UK.

Published: May 2003

Transient myeloid disorder is a unique self-regressing neoplasia specific to Down's syndrome. The transcription factor GATA1 is needed for normal growth and maturation of erythroid cells and megakaryocytes. Mutations in GATA1 have been reported in acute megakaryoblastic leukaemia in Down's syndrome. We aimed to investigate changes in GATA1 in patients with Down's syndrome and either transient myeloid disorder (n=10) or acute megakaryoblastic leukaemia (n=6). We recorded mutations eliminating exon 2 from GATA1 in all patients with transient myeloid disorder (age 0-24 days) and in all with acute megakaryoblastic leukaemia (age 14-38 months). The range of mutations did not differ between patients with each disorder. Patients with transient myeloid disorder with mutations in GATA1 can regress spontaneously to complete remission, and mutations do not necessarily predict later acute megakaryoblastic leukaemia.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(03)13266-7DOI Listing

Publication Analysis

Top Keywords

transient myeloid
20
myeloid disorder
20
down's syndrome
16
acute megakaryoblastic
16
megakaryoblastic leukaemia
16
mutations gata1
12
syndrome transient
8
gata1 patients
8
patients transient
8
gata1
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!